Fairmount Funds Management LLC — Form 4 insider transactions

Fairmount Funds Management LLC — Full 13F portfolio →

Buys and sells reported on SEC Form 4 — filed within two business days of each trade when a filer's ownership in a stock crosses 10%. This is the fastest public window into what the manager is doing.

Transaction date Activity Security Shares Price Total Filing
2026-09-03 Disposition Apogee Therapeutics, Inc. 51,166 — — SEC filing
2026-09-03 Disposition Apogee Therapeutics, Inc. 340,855 — — SEC filing
2026-08-07 Opt exercise Apogee Therapeutics, Inc. 10,370 $43.85 $454,724 SEC filing
2026-08-07 Opt exercise Apogee Therapeutics, Inc. 31,838 $17.00 $541,246 SEC filing
2026-07-16 Buy CRESCENT BIOPHARMA, INC. 853,450 $14.50 $12,375,025 SEC filing
2026-07-01 Sell Oruka Therapeutics, Inc. 3,553,410 $84.43 $300,014,406 SEC filing
2026-07-01 Conversion Oruka Therapeutics, Inc. 3,553,410 — — SEC filing
2026-06-23 Sell Spyre Therapeutics, Inc. 4,684,781 $85.31 $399,658,667 SEC filing
2026-06-23 Conversion Spyre Therapeutics, Inc. 666,680 — — SEC filing
2026-05-11 Buy Viridian Therapeutics, Inc.\DE 1,176,470 $17.00 $19,999,990 SEC filing

How Form 4 differs from 13F

13F filings are quarterly snapshots, up to 45 days late. Form 4 is transaction-level and lands within two business days — but only covers stocks where the filer reports beneficial ownership above 10%. Pair the two: 13F for the whole portfolio, Form 4 for what the largest holders are doing right now.

All insider transactions →